Seaview Investment Managers LLC Sells 948 Shares of Eli Lilly and Company $LLY

Seaview Investment Managers LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.7% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 13,246 shares of the company’s stock after selling 948 shares during the quarter. Eli Lilly and Company comprises 2.2% of Seaview Investment Managers LLC’s portfolio, making the stock its 20th largest holding. Seaview Investment Managers LLC’s holdings in Eli Lilly and Company were worth $10,326,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the 1st quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $27,000. Financial Gravity Companies Inc. bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $31,000. Bare Financial Services Inc increased its position in shares of Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the period. Finally, Blume Capital Management Inc. raised its stake in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,009.26 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a market capitalization of $954.13 billion, a P/E ratio of 49.38, a PEG ratio of 1.13 and a beta of 0.37. The stock’s 50 day moving average is $918.84 and its 200 day moving average is $809.30. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the previous year, the business earned $1.18 earnings per share. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Wall Street Analyst Weigh In

LLY has been the subject of several research analyst reports. National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a report on Monday. Scotiabank started coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price for the company. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research report on Monday, November 10th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Berenberg Bank increased their price objective on Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,087.32.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.